Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Randomized Phase 3 DeLLphi-304 Study - Tarlatamab, a DLL3-Targeting BiTE, Compared to Standard of Care in Patients With Relapsed SCLC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Luis Paz-Ares
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Luis Paz-Ares
Login to view comments.
Click here to Login
